PHAC to publicly disclose conflicts of interest of external advisors serving on advisory committees

Collier, Roger
August 2011
CMAJ: Canadian Medical Association Journal;8/9/2011, Vol. 183 Issue 11, pE707
Academic Journal
The article reports that Public Health Agency of Canada (PHAC) is ready to publicly disclose its financial ties to industry without requiring external experts serving on advisory committees. PHAC Media Relations Advisor Charlene Wiles mentions that the agency needs external experts to privately disclose potential of conflict of interest, prior to providing service, and during their term of service. It highlights the policy of the U.S. Food and Drug Administration regarding the context.


Related Articles

  • FDA drafts new guidance for panelists' conflicts.  // Medical Technology & Devices Week;3/26/2007, Vol. 5 Issue 13, p5 

    The article reports on the issuance of a draft guidance by the U.S. Food and Drug Administration dealing with conflict of interests among the agency's advisory panels. The FDA said that the new guidance will increase transparency and enhance public trust. Under the guidance, a prospective panel...

  • FDA proposes conflict of interest guidelines.  // Nation's Health;Jun/Jul2007, Vol. 37 Issue 5, p8 

    The article reports that the U.S. Food and Drug Administration (FDA) is considering new conflicts of interest requirements for committee members who advise the agency on regulatory actions. The agency currently screens all prospective advisory committee members before each meeting to determine...

  • FDA Seeks Stricter Guidelines For Advisory Approval Panels.  // Quality Progress;May2007, Vol. 40 Issue 5, p12 

    The article reports on the proposal of the U.S. Food and Drug Administration (FDA) to create guidelines that will reduce conflicts of interest among people who approve drugs and medical devices. The new rules will disqualify physicians and scientific researchers from serving on FDA advisory...

  • An All-or-Nothing Approach Could Tie FDA's Hands. Bush, Laura // BioPharm International;Sep2006, Vol. 19 Issue 9, p10 

    The author reflects on the new guidance developed by the U.S. Food and Drug Administration about potential conflicts of interest among advisory committee members. He points out that it is better to become a purist, however it may have unexpected results. He cites an example about what happened...

  • FDA steps up disclosure rules following conflict of interest claims.  // Pharmaceutical Technology Europe;Oct2006, Vol. 18 Issue 10, p11 

    The article reports on the survey about the plans of the U.S. Food & Drug Administration to enhance its process for disclosing conflicts of interest of advisory board members. It is found out that 18.4% of the 997 employees responded for non-scientific reasons to inappropriately exclude...

  • Experts on the Take. Mokhiber, Russell // Multinational Monitor;Nov2000, Vol. 21 Issue 11, p29 

    Reveals that experts hired by the United States Food and Drug Administration have financial relationships with pharmaceutical companies. Percentage of experts with financial interest in the pharmacy industry or in topic they are asked to evaluate; Implications of their interests to the health...

  • FDA Seeks to Revamp Panels. Agres, Ted // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, p6 

    The article reports on the plan of the U.S. Food and Drug Administration to reassess how it selects and uses advisory committee members having potential financial conflicts of interest with pharmaceutical companies. FDA plans to hold a public hearing as a prelude to updating guidance on how it...

  • BioPharm Editorial Board Member Awarded Medal.  // BioPharm International;Aug2006, Vol. 19 Issue 8, p20 

    The article reports that editorial advisory board member of BioPharm International, Ajaz Hussain, had been named as the recipient of the 2006 International Pharmaceutical Section Medal to be given by the International Pharmaceutical Federation (FIP) in Brazil on August 31, 2006. According to FIP...

  • FDA forms risk management advisory panel.  // Medical Marketing & Media;Feb2002, Vol. 37 Issue 2, p30 

    Reports on the development of an advisory panel by the U.S. Food and Drug Administration. Expertise in risk perception and clinical pharmacology; Detection of medication errors.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics